Increase in ozempix sales in Russia exceeds fourfold within six months
In the first half of 2025, Russia has witnessed a significant increase in the demand for semaglutide-based weight loss drugs, with sales reaching an impressive 12.5 billion rubles (~$150 million) and over 2.2 million packages sold[1][3]. This boom can be attributed to several key factors.
The market for these drugs has experienced exponential growth, with sales increasing sixfold compared to 2024[2]. In just three months, manufacturers released approximately 2.4 million packages, a tenfold year-on-year increase[2]. The demand, both physical and monetary, has risen by around 30% compared to the last quarter of 2024[2].
One of the main reasons for this surge is the improved affordability of these drugs. Russian pharmaceutical companies have produced generic semaglutide drugs, such as Semavik by Geropharm and Kvisenta by Promomed, at significantly lower prices than imported originals[2][3]. This is due in part to compulsory licensing, which allows local production without patent holder consent[2][3].
These drugs, originally developed for type 2 diabetes, are now widely used for weight management due to their appetite-suppressing effects[3]. In fact, Ozempic has been added to Russia’s official obesity treatment guidelines, increasing physician endorsement and adoption[3]. Public interest in weight management is high, with 80% of Russians attempting to lose weight recently, and about 43% either using or considering weight-loss medications[2].
The media and social networks have also played a role in amplifying awareness and demand for semaglutide-based treatments[3]. However, it's important to note that obesity remains a global issue, often referred to as the pandemic of the 21st century[4]. As of 2025, the official figure for obesity in Russia stood at 24.6%, with a higher rate among women (27.4%) compared to men (20.6%)[1].
Despite the surge in demand, the price of these drugs has decreased by 8-10%, with an average price per syringe currently ranging from 5300 to 5700 rubles[1]. Before 2022, the drug "Ozempic" was imported to Russia from the US, but supplies ceased after geopolitical tensions intensified[5]. However, domestic alternatives quickly filled the market, ensuring continued access to these treatments.
As the fight against obesity continues, dieticians have started including semaglutide in their clinical recommendations for obesity therapy[6]. The Chief Dietitian of the Ministry of Health advises critically evaluating advertising of diets and 'healthy' food products[7]. With the projected number of people suffering from obesity set to reach 3.8 billion by 2050[8], it's clear that these treatments will play a crucial role in managing this global health crisis.
References: [1] [Link to source 1] [2] [Link to source 2] [3] [Link to source 3] [4] [Link to source 4] [5] [Link to source 5] [6] [Link to source 6] [7] [Link to source 7] [8] [Link to source 8]
The market for semaglutide-based treatments, including those for weight management, has seen a tremendous growth in Russia, with sales reaching over 12.5 billion rubles and over 2.2 million packages sold in the first half of 2025. This surge is largely due to the increased affordability of generic versions, a result of compulsory licensing and local production.
